EH3
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. … Read more
EH3 (EH3) - Total Assets
Latest total assets as of September 2025: €659.81 Million EUR
Based on the latest financial reports, EH3 (EH3) holds total assets worth €659.81 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
EH3 - Total Assets Trend (2021–2024)
This chart illustrates how EH3’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
EH3 - Asset Composition Analysis
Current Asset Composition (December 2024)
EH3's total assets of €659.81 Million consist of 86.9% current assets and 13.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 17.7% |
| Accounts Receivable | €122.28 Million | 17.8% |
| Inventory | €166.05 Million | 24.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €16.39 Million | 2.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how EH3's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EH3's current assets represent 86.9% of total assets in 2024, an increase from 82.3% in 2021.
- Cash Position: Cash and equivalents constituted 17.7% of total assets in 2024, down from 20.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, unchanged from 2.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 24.2% of total assets.
EH3 Competitors by Total Assets
Key competitors of EH3 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
EH3 - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - EH3 generates 0.33x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - EH3 is currently not profitable relative to its asset base.
EH3 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.45 | 3.23 | 3.23 |
| Quick Ratio | 2.43 | 2.11 | 2.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €446.10 Million | € 448.66 Million | € 448.66 Million |
EH3 - Advanced Valuation Insights
This section examines the relationship between EH3's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | -17.6% |
| Total Assets | €685.35 Million |
| Market Capitalization | $245.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values EH3's assets below their book value (0.36 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: EH3's assets decreased by 17.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for EH3 (2021–2024)
The table below shows the annual total assets of EH3 from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €685.35 Million | -17.60% |
| 2023-12-31 | €831.68 Million | -6.15% |
| 2022-12-31 | €886.18 Million | -17.03% |
| 2021-12-31 | €1.07 Billion | -- |